Effects of Proton Pump Inhibitors Intake ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Effects of Proton Pump Inhibitors Intake During Chemoradiotherapy for Rectal Cancer: a Retrospective Cohort Study.
Auteur(s) :
Bridoux, Marie [Auteur]
Service d'oncologie médicale (CHRU Lille)
Le Deley, Marie-Cecile [Auteur]
Service de Biostatistiques [CHRU Lille]
Bertrand, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Simon, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Sylla, Dienabou [Auteur]
Service de Biostatistiques [CHRU Lille]
Mirabel, Xavier [Auteur]
Service d'oncologie médicale (CHRU Lille)
Turpin, Anthony [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service d'oncologie médicale (CHRU Lille)
Le Deley, Marie-Cecile [Auteur]
Service de Biostatistiques [CHRU Lille]
Bertrand, Nicolas [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Simon, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Sylla, Dienabou [Auteur]
Service de Biostatistiques [CHRU Lille]
Mirabel, Xavier [Auteur]
Service d'oncologie médicale (CHRU Lille)
Turpin, Anthony [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Titre de la revue :
International Journal of Gastrointestinal Cancer
Nom court de la revue :
J Gastrointest Cancer
Numéro :
54
Pagination :
545-553
Éditeur :
Humana Press
Date de publication :
2022-05-17
ISSN :
1941-6636
Mot(s)-clé(s) :
Rectal cancer
Capecitabine
Chemoradiotherapy
Proton pump inhibitors
Capecitabine
Chemoradiotherapy
Proton pump inhibitors
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Purpose
Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide and are involved in several drug interactions. Recently, several studies have suggested that PPIs may interfere with the efficacy of ...
Lire la suite >Purpose Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide and are involved in several drug interactions. Recently, several studies have suggested that PPIs may interfere with the efficacy of capecitabine. This study primarily aimed to investigate the effects of PPI intake on the pathologic response rate of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy with capecitabine. Method A retrospective study was conducted at a French Comprehensive Cancer Center. Patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by surgery were included in the study. Demographic parameters, treatment characteristics, survival data, and PPI intake data were collected. Frequencies and percentages were reported for categorical variables and medians and interquartile ranges for continuous variables. Distribution of variables was compared according to PPI treatment using the chi-square test or Fisher’s exact test for categorical data and nonparametric Wilcoxon tests for continuous variables. Survival data were estimated using the Kaplan–Meier method and compared using the log-rank test. Results In total, 215 patients were included, of whom 135 (62.8%) were men. The PPI intake frequency was 16.1%. The rate of complete pathological response was not significantly lower in patients on PPIs than in those not on PPIs (8.7% vs. 19%, p = 0.36). PPI intake was not associated with a statistically significant decrease in recurrence-free survival (hazard ratio [HR] = 1.26, 95% confidence interval [CI] 0.61–2.60, p = 0.54) or overall survival (HR = 0.95, 95% CI 0.33–2.76, p = 0.93). Conclusion No significant association was observed between PPI co-medication and complete pathological response or survival in patients treated for locally advanced rectal cancer. However, the safety of PPIs could not be confirmed. Further ancillary studies of prospective clinical trials or studies using the Health Data Hub are necessary to explore the effects of PPIs on rectal cancer more accurately.Lire moins >
Lire la suite >Purpose Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide and are involved in several drug interactions. Recently, several studies have suggested that PPIs may interfere with the efficacy of capecitabine. This study primarily aimed to investigate the effects of PPI intake on the pathologic response rate of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy with capecitabine. Method A retrospective study was conducted at a French Comprehensive Cancer Center. Patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by surgery were included in the study. Demographic parameters, treatment characteristics, survival data, and PPI intake data were collected. Frequencies and percentages were reported for categorical variables and medians and interquartile ranges for continuous variables. Distribution of variables was compared according to PPI treatment using the chi-square test or Fisher’s exact test for categorical data and nonparametric Wilcoxon tests for continuous variables. Survival data were estimated using the Kaplan–Meier method and compared using the log-rank test. Results In total, 215 patients were included, of whom 135 (62.8%) were men. The PPI intake frequency was 16.1%. The rate of complete pathological response was not significantly lower in patients on PPIs than in those not on PPIs (8.7% vs. 19%, p = 0.36). PPI intake was not associated with a statistically significant decrease in recurrence-free survival (hazard ratio [HR] = 1.26, 95% confidence interval [CI] 0.61–2.60, p = 0.54) or overall survival (HR = 0.95, 95% CI 0.33–2.76, p = 0.93). Conclusion No significant association was observed between PPI co-medication and complete pathological response or survival in patients treated for locally advanced rectal cancer. However, the safety of PPIs could not be confirmed. Further ancillary studies of prospective clinical trials or studies using the Health Data Hub are necessary to explore the effects of PPIs on rectal cancer more accurately.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T02:39:35Z
2023-08-23T06:44:58Z
2023-08-23T06:44:58Z